The ASGR1 Knockout NCI-H1703 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ASGR1 gene in the NCI-H1703 cell line. This product provides a heterogeneous pool of cells carrying diverse loss-of-function mutations introduced by CRISPR/Cas9-mediated genome editing, offering a robust model for studying ASGR1 function without the limitations of clonal selection. The polyclonal format ensures representation of multiple knockout alleles, enabling the study of gene disruption effects at the population level.
NCI-H1703 is a human lung squamous cell carcinoma line derived from a 55-year-old male. This adherent epithelial cell line serves as a well-characterized model for non-small cell lung cancer (NSCLC), particularly for research into squamous cell carcinoma pathogenesis, proliferation, and metastasis.
ASGR1 encodes the major subunit of the asialoglycoprotein receptor (ASGPR), which heterodimerizes with ASGR2 to mediate clathrin-dependent endocytosis of desialylated glycoproteins, followed by lysosomal degradation. Upstream regulators such as HNF4A, IL-6, STAT3, and TNF-?? modulate ASGR1 expression, while downstream signaling through factors including cathepsins, NF-??B, STAT3, and lysosomal enzymes propagates its effects. The receptor interacts with the AP-2 adaptor complex, clathrin, and HGS during endocytic vesicle formation, and its trafficking involves Rab5, EEA1, and LAMP1 on route to lysosomes. Through these connections, ASGR1 influences JAK-STAT signaling, apoptosis, and cell proliferation.
In NCI-H1703 lung squamous carcinoma cells, disruption of ASGR1 abrogates ASGPR-mediated glycoprotein clearance, potentially altering cell surface glycosylation and disrupting glycoprotein homeostasis. Because aberrant glycosylation is a hallmark of cancer, this knockout model enables investigation of how ASGPR pathway loss influences tumor cell behavior, including proliferation, apoptosis, and migration. The polyclonal population captures a range of knockout efficiencies, reflecting heterogeneous effects that may intersect with inflammatory signals (TNF-??, IL-6) and oncogenic transcription factors like STAT3, which are frequently activated in NSCLC.
This ASGR1 knockout polyclonal cell product is suited for functional studies using Western blotting for protein confirmation, RT-qPCR for transcript analysis, flow cytometry to assess receptor loss, lectin-binding uptake assays to quantify endocytic activity, immunofluorescence for localization, and functional assays such as Annexin V/PI apoptosis detection, MTS/CCK-8 proliferation measurement, and Transwell migration assays. Applications include dissecting ASGR1??s role in lung cancer tumorigenesis, exploring ASGPR-mediated drug delivery, identifying glycan-based biomarkers, and performing functional genomics screens targeting endocytosis and glycoprotein catabolism. For further information, contact Ascent Research.
